Company

CRISPR Therapeutics

Pharmaceutical intelligence for CRISPR Therapeutics with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 0
Catalysts: 1
Assets: 1

Recent signals

No signals indexed for this entity yet.

Upcoming catalysts(1)

Phase I Readout

CRISPR Therapeutics — CTX130

Allogeneic CAR-T early data tests off-the-shelf cell therapy viability in solid tumors.

June 22, 2026 · Phase I

Regulatory activity

No signals indexed for this entity yet.

Clinical activity

No signals indexed for this entity yet.

Competitive activity

No signals indexed for this entity yet.

Assets

CTX130 →

Therapeutic areas

Oncology →

Indications

Renal cell carcinoma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.